alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 60 studies with an author at Université Paris Cité (FR) (page 1 of 3) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association Between Age at Diabetes Onset and Subsequent Risk of Dementia

✓ Peer-reviewed alzhub usefulness score 77 out of 100. JAMA 2021-04-01

Among 10 095 participants (67.3% men; aged 35-55 years in 1985-1988), a total of 1710 cases of diabetes and 639 cases of dementia were recorded over a median follow-up of 31.7 years. 3 key findings →

Design: cohort study Participants: 95 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Alzheimer's research & therapy 2023-02-28

Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). 4 key findings →

Participants: 182 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

✓ Peer-reviewed alzhub usefulness score 75 out of 100. JAMA neurology 2021-12-01

This study suggests that plasma GFAP is a sensitive biomarker for detecting and tracking reactive astrogliosis and Aβ pathology even among individuals in the early stages of AD. 5 key findings →

Design: cross-sectional Participants: 300 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study

✓ Peer-reviewed alzhub usefulness score 75 out of 100. Archives of internal medicine 2002-10-01

Median follow-up increased from 2.0 years in the double-blind trial to 3.9 years overall. 2 key findings →

Participants: 1,485 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

✓ Peer-reviewed alzhub usefulness score 73 out of 100. Acta neuropathologica 2022-09-06

Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. 2 key findings →

Participants: 8,074 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association between socioeconomic status and the development of mental and physical health conditions in adulthood: a multi-cohort study

✓ Peer-reviewed alzhub usefulness score 73 out of 100. The Lancet. Public health 2020-01-31

During 1 110 831 person-years at risk, we recorded 245 573 hospitalisations in the Finnish cohorts; the corresponding numbers in the UK study were 60 946 hospitalisations in 186 572 person-years. 4 key findings →

Design: cohort study Participants: 9,838 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Midlife and late‐life population attributable fractions of risk factors for dementia in the United States: The Dementia Risk Prediction Project

✓ Peer-reviewed alzhub usefulness score 73 out of 100. Alzheimer s & Dementia 2026-01-01

Midlife and late-life risk factors contributed to 22.7% and 16.5% of total dementia cases, respectively. 5 key findings →

Design: meta-analysis Participants: 37,931 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study

✓ Peer-reviewed alzhub usefulness score 72 out of 100. BMJ (Clinical research ed.) 2019-08-07

Adherence to the Life Simple 7 ideal cardiovascular health recommendations in midlife was associated with a lower risk of dementia later in life. 4 key findings →

Design: cohort study Participants: 7,899 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study

✓ Peer-reviewed alzhub usefulness score 71 out of 100. PLoS Medicine 2019-08-02

More frequent social contact at age 60 years was associated with lower dementia risk (hazard ratio [HR] for each SD higher social contact frequency = 0.88 [95% CI 0.79, 0.98], p = 0.02); effect size of the association of social contact at 50 or 70 years with dementia was similar (0.92 [95% CI 0.83, 1.02], p = 0.13 and 0.91 [95% CI 0.78, 1.06], p = 0.23, respectively) but not statistically significant. 3 key findings →

Design: cohort Participants: 10,228 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study

✓ Peer-reviewed alzhub usefulness score 70 out of 100. The Lancet. Public health 2019-12-16

Multimorbidity (hazard ratio [HR] 4·12 [95% CI 3·41-4·98]), frailty (HR 2·38 [95% CI 1·93-2·93]), and disability (HR 1·73 [95% CI 1·34-2·22]) were associated with increased risk of mortality; these associations were not modified by socioeconomic status. 2 key findings →

Design: cohort study Participants: 308 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Asundexian for Secondary Stroke Prevention

✓ Peer-reviewed alzhub usefulness score 68 out of 100. New England Journal of Medicine 2026-04-15

Among 12,327 patients who underwent randomization (6162 to the asundexian group and 6165 to the placebo group), the incidence of ischemic stroke was lower in the asundexian group than in the placebo group (6.2% vs. 8.4%; cause-specific hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.84; P<0.001). 5 key findings →

Design: clinical trial Participants: 12,327 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2022-07-01

In this genetic association study, a novel variant associated with AD was identified: R251G always coinherited with ε4 on the APOE gene, which mitigates the ε4-associated AD risk. 5 key findings →

Design: case-control study Participants: 37 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sex differences and the role of education in cognitive ageing: analysis of two UK-based prospective cohort studies

✓ Peer-reviewed alzhub usefulness score 66 out of 100. The Lancet. Public health 2021-02-01

Our findings suggest that decreasing disparities between sexes in education, due to secular increases in educational opportunities, could attenuate sex differences in dementia risk and cognitive decline in the future. 1 key finding →

Design: cohort study Participants: 924 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

New insights into the genetic etiology of Alzheimer's disease and related dementias

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Nature genetics 2022-04-04

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2022-01-01

Alzheimer disease comorbid pathologic characteristics are common and are associated with more rapid cognitive decline in patients with dementia with Lewy bodies (DLB); therefore, it is anticipated that plasma p-tau concentrations may have utility in assessing cognitive impairment in individuals with this disorder. 4 key findings →

Design: cohort study Participants: 371 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study

✓ Peer-reviewed alzhub usefulness score 66 out of 100. PLoS medicine 2020-08-20

The ε4 allele of apolipoprotein E (APOE) gene and increasing age are two of the most important known risk factors for developing Alzheimer disease (AD). 4 key findings →

Design: cohort study Participants: 1,593 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Neurology 2020-06-25

All synaptic biomarkers tested had a good discriminatory power to distinguish patients with AD abnormal CSF from those with non-AD disorders. 4 key findings →

Design: cross-sectional Participants: 81 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effects of Meditation Training and Non-Native Language Training on Cognition in Older Adults: A Secondary Analysis of a Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA network open 2023-07-03

Among 137 randomized participants, 2 were excluded for not meeting eligibility criteria, leaving 135 (mean [SD] age, 69.3 [3.8] years; 83 female [61%]) eligible for analysis. 3 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed